Finance

Lists
603259:SHA
WuXi AppTec Co Ltd
CNÂ¥156.67
-1.38%
(-2.19) 1D
Sep 15, 3:00:03 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603259...
Open
CNÂ¥157.10
High
CNÂ¥159.68
Low
CNÂ¥155.92
Mkt. cap
483.91B
Avg. vol.
56.74M
Volume
26.11M
Dividend
1.33%
Quarterly dividend
CNÂ¥0.52
Ex-dividend date
Sep 4, 2026
P/E ratio
21.31
52-wk high
CNÂ¥173.60
52-wk low
CNÂ¥87.09
EPS
CNÂ¥7.35
Shares outstanding
1.05B
No. of employees
36K
Open
CNÂ¥157.10
High
CNÂ¥159.68
Low
CNÂ¥155.92
Mkt. cap
483.91B
Avg. vol.
56.74M
Volume
26.11M
Dividend
1.33%
Quarterly dividend
CNÂ¥0.52
Ex-dividend date
Sep 4, 2026
P/E ratio
21.31
52-wk high
CNÂ¥173.60
52-wk low
CNÂ¥87.09
EPS
CNÂ¥7.35
Shares outstanding
1.05B
No. of employees
36K
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Co Ltd
CEOSteve Yang | Ge Li
Employees35.6K
FoundedDec 1, 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
12.04B
10.97B
12.44B
16.46B
Cost of goods sold
6.07B
4.91B
6.17B
-
Cost of revenue
6.07B
4.91B
6.17B
-
Research and development expenses
311.73M
236.94M
266.96M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
854.49M
853.67M
891.80M
-
Operating expense
1.38B
1.26B
1.22B
-
Total operating expenses
7.45B
6.17B
7.39B
-
Operating income
4.59B
4.80B
5.04B
-
Other non operating income
-470.36M
281.37M
-266.37M
-
EBT including unusual items
5.13B
6.75B
5.61B
-
EBT excluding unusual items
5.11B
6.95B
5.19B
-
Income tax expense
1.55B
1.09B
936.77M
-
Effective tax rate
30.19%
16.12%
16.71%
-
Other operating expenses
57.96M
25.84M
726.05K
-
Net income
3.51B
7.08B
4.65B
-
Net profit margin
29.18%
64.49%
37.40%
-
Earnings per share
1.24
1.42
1.57
2.20
Interest and investment income
1.21B
1.87B
439.82M
-
Interest expense
-226.71M
-
-30.95M
-
Net interest expenses
981.72M
1.87B
408.87M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5.21B
5.61B
5.85B
-
Gain or loss from assets sale
-158.03M
218.40M
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps